Najah Abi Gerges
AnaBios Corporation, USA
Biography
Najah Abi Gerges, PhD, is the Vice President of Research and Development at AnaBios Corporation, USA. He holds a PhD in Cardiac Physiology from Paris XI University, France. Prior to joining AnaBios, he was involved in drug discovery programs at AstraZeneca. With over 17 years in the pharmaceutical industry, he is an innovative Leader, having made substantial contributions to drug approvals (Tagrisso®), research across several areas of cardiac physiology and pharmacology resulting in over 40 published articles, and novel paradigms to advance cardiovascular translational science. He is the Editor for the Journal of Pharmacological and Toxicological Methods, Vice President Elect for Southern California Chapter of the Society of Toxicology. His interest lies in drug discovery and development.
Abstract
Abstract : Integrating adult human primary cardiomyocytes into early cardiac safety assessment